olutasidenib   Click here for help

GtoPdb Ligand ID: 10319

Synonyms: example 26 [US9834539B2] | FT-2102 | FT2102 | Rezlidhia®
Approved drug PDB Ligand
olutasidenib is an approved drug (FDA (2022))
Compound class: Synthetic organic
Comment: Olutasidenib (FT-2102) is an orally available and brain penetrant inhibitor of mutant IDH1 that is being developed by Forma Therapeutics for antineoplastic potential [1]. Activating mutations in IDH1 (e.g. IDH1R132H) drive cancer initiation and growth by enhancing the formation of the oncometabolite 2-hydroxyglutarate (2HG) [3]. Pharmacological inhibition of mutant IDH1 blocks 2HG production as a means to restore normal cellular differentiation. This is the same mechanism of action as ivosidenib (Tibsovo®) that was FDA approved in 2018.
FT-2102 is claimed as example 26 (I-14) in Forma Tm2's patent US9834539B2 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 90.68
Molecular weight 354.09
XLogP 4.41
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES N#Cc1ccc(c(=O)n1C)NC(c1cc2cc(Cl)ccc2[nH]c1=O)C
Isomeric SMILES N#Cc1ccc(c(=O)n1C)N[C@H](c1cc2cc(Cl)ccc2[nH]c1=O)C
InChI InChI=1S/C18H15ClN4O2/c1-10(21-16-6-4-13(9-20)23(2)18(16)25)14-8-11-7-12(19)3-5-15(11)22-17(14)24/h3-8,10,21H,1-2H3,(H,22,24)/t10-/m0/s1
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
isocitrate dehydrogenase (NADP(+)) 1 Hs Inhibitor Inhibition 6.0 – 7.0 pIC50 - 2
pIC50 6.0 – 7.0 (IC50 1x10-6 – 1x10-7 M) [2]
Description: Inhibition of mutant IDH1 R132H and R132C in an enzymatic assay measuring inhibition of 2-HG production.